Alexandria Capital’s Novartis NVS Stock Holding History

Alexandria Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$681K	Buy	8,323 +814	+11%	+$73.2K	0.06%	171
2021 Q2	$685K	Sell	7,509 -734	-9%	-$65.4K	0.06%	172
2021 Q1	$705K	Hold	8,243	–	–	0.07%	168
2020 Q4	$778K	Sell	8,243 -150	-2%	-$13.1K	0.08%	154
2020 Q3	$730K	Hold	8,393	–	–	0.09%	156
2020 Q2	$733K	Buy	8,393 +79	+1%	+$6.82K	0.1%	150
2020 Q1	$685K	Sell	8,314 -575	-6%	-$51.3K	0.11%	144
2019 Q4	$842K	Sell	8,889 -2,065	-19%	-$185K	0.11%	148
2019 Q3	$952K	Sell	10,954 -555	-5%	-$49.8K	0.14%	134
2019 Q2	$1.05M	Sell	11,509 -2,563	-18%	-$217K	0.15%	137
2019 Q1	$1.21M	Sell	14,072 -301	-2%	-$24.2K	0.18%	132
2018 Q4	$1.1M	Sell	14,373 -14,149	-50%	-$1.1M	0.18%	131
2018 Q3	$2.2M	Sell	28,522 -2,677	-9%	-$198K	0.32%	94
2018 Q2	$2.11M	Sell	31,199 -962	-3%	-$66.4K	0.32%	100
2018 Q1	$2.33M	Sell	32,161 -78	-0.2%	-$5.94K	0.35%	96
2017 Q4	$2.42M	Buy	32,239 +32,060	+17,911%	+$2.42M	0.35%	91
2017 Q3	$14K	Hold	179	–	–	﹤0.01%	380
2017 Q2	$13K	Hold	179	–	–	﹤0.01%	393
2017 Q1	$12K	Hold	179	–	–	﹤0.01%	392
2016 Q4	$12K	Hold	179	–	–	﹤0.01%	391
2016 Q3	$13K	Hold	179	–	–	﹤0.01%	386
2016 Q2	$13K	Hold	179	–	–	﹤0.01%	372
2016 Q1	$12K	Hold	179	–	–	﹤0.01%	394
2015 Q4	$14K	Hold	179	–	–	﹤0.01%	407
2015 Q3	$15K	Hold	179	–	–	﹤0.01%	362
2015 Q2	$16K	Hold	179	–	–	﹤0.01%	367
2015 Q1	$16K	Buy	+179	New	+$15.9K	0.01%	332
2013 Q3	–	Sell	-223	Closed	-$14K	–	653
2013 Q2	$14K	Buy	+223	New	+$14.5K	0.01%	348

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Alexandria Capital's NVS Position: Q3 2021 in Review

Alexandria Capital increased its Novartis (NVS) stake by 11% in Q3 2021, buying an estimated $73.2K and bringing the position to 8,323 shares worth $681K. The position accounts for 0.06% of the portfolio, ranked #171.

Alexandria Capital first reported a position in NVS in Q2 2013 and has held it in 28 quarters since. The position peaked at $2.42M in Q4 2017. 1,081 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

Alexandria Capital held 8,323 shares of Novartis worth $681K as of Q3 2021.
Alexandria Capital bought 814 Novartis shares in Q3 2021, an estimated $73.2K.
Novartis made up 0.06% of Alexandria Capital's portfolio in Q3 2021, its #171 holding.
Alexandria Capital first reported a position in Novartis in Q2 2013 and has held it in 28 quarters since.
Alexandria Capital's Novartis position peaked at $2.42M in Q4 2017.
1,081 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.